WO2002005858A3 - Fluorescent agents for real-time measurement of organ function - Google Patents

Fluorescent agents for real-time measurement of organ function Download PDF

Info

Publication number
WO2002005858A3
WO2002005858A3 PCT/US2001/022901 US0122901W WO0205858A3 WO 2002005858 A3 WO2002005858 A3 WO 2002005858A3 US 0122901 W US0122901 W US 0122901W WO 0205858 A3 WO0205858 A3 WO 0205858A3
Authority
WO
WIPO (PCT)
Prior art keywords
agent
organ function
real
time measurement
fluorescent agents
Prior art date
Application number
PCT/US2001/022901
Other languages
French (fr)
Other versions
WO2002005858A2 (en
Inventor
Carlos Rabito
Original Assignee
Gen Hospital Corp
Carlos Rabito
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, Carlos Rabito filed Critical Gen Hospital Corp
Priority to EP01959055A priority Critical patent/EP1427451A2/en
Priority to US10/204,511 priority patent/US20030215391A1/en
Priority to AU2001280647A priority patent/AU2001280647A1/en
Priority to JP2002511789A priority patent/JP2004517041A/en
Priority to CA002418206A priority patent/CA2418206A1/en
Publication of WO2002005858A2 publication Critical patent/WO2002005858A2/en
Publication of WO2002005858A3 publication Critical patent/WO2002005858A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0028—Oxazine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds

Abstract

A fluorescent agent for monitoring organ function, such as glomerular filtration, renal blood flow, or hepatic function. The agent is injected into a subject and the fluorescence monitored in vivo via time-resolved fluorescent techniques. The agent is a lanthanide ion chelated to a polyaminopolyacetic acid analog. A new clearance agent is also proposed based on a tetraazamacrocycle. Such a clearance agent also finds applications in other fields where fluorescence detection is exploited.
PCT/US2001/022901 2000-07-19 2001-07-19 Fluorescent agents for real-time measurement of organ function WO2002005858A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP01959055A EP1427451A2 (en) 2000-07-19 2001-07-19 Fluorescent agents for real-time measurement of organ function
US10/204,511 US20030215391A1 (en) 2001-07-19 2001-07-19 Fluorescent agents for real-time measurement of organ function
AU2001280647A AU2001280647A1 (en) 2000-07-19 2001-07-19 Fluorescent agents for real-time measurement of organ function
JP2002511789A JP2004517041A (en) 2000-07-19 2001-07-19 Fluorescent agents for real-time measurement of organic functional groups
CA002418206A CA2418206A1 (en) 2000-07-19 2001-07-19 Fluorescent agents for real-time measurement of organ function

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21936200P 2000-07-19 2000-07-19
US60/219,362 2000-07-19
US09/631,138 US6440389B1 (en) 2000-07-19 2000-08-02 Fluorescent agents for real-time measurement of organ function
US09/631,138 2000-08-02

Publications (2)

Publication Number Publication Date
WO2002005858A2 WO2002005858A2 (en) 2002-01-24
WO2002005858A3 true WO2002005858A3 (en) 2003-07-24

Family

ID=26913816

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/022901 WO2002005858A2 (en) 2000-07-19 2001-07-19 Fluorescent agents for real-time measurement of organ function

Country Status (6)

Country Link
US (2) US6440389B1 (en)
EP (1) EP1427451A2 (en)
JP (1) JP2004517041A (en)
AU (1) AU2001280647A1 (en)
CA (1) CA2418206A1 (en)
WO (1) WO2002005858A2 (en)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067111B1 (en) 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
PL212211B1 (en) * 2000-06-02 2012-08-31 Regents Board Of Ethylenedicysteine (ec)-drug conjugates
DE10105592A1 (en) * 2001-02-06 2002-08-08 Achim Goepferich Placeholder for drug release in the frontal sinus
US20030215391A1 (en) * 2001-07-19 2003-11-20 Carlos Rabito Fluorescent agents for real-time measurement of organ function
GB0214340D0 (en) * 2002-06-21 2002-07-31 Multipex Photonics Ltd Apparatus for characterising a sample by an optical pulse
US8317816B2 (en) 2002-09-30 2012-11-27 Acclarent, Inc. Balloon catheters and methods for treating paranasal sinuses
US9050378B2 (en) * 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
US8894614B2 (en) 2004-04-21 2014-11-25 Acclarent, Inc. Devices, systems and methods useable for treating frontal sinusitis
US9554691B2 (en) * 2004-04-21 2017-01-31 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US20070208252A1 (en) 2004-04-21 2007-09-06 Acclarent, Inc. Systems and methods for performing image guided procedures within the ear, nose, throat and paranasal sinuses
US8864787B2 (en) 2004-04-21 2014-10-21 Acclarent, Inc. Ethmoidotomy system and implantable spacer devices having therapeutic substance delivery capability for treatment of paranasal sinusitis
US20190314620A1 (en) 2004-04-21 2019-10-17 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures
US7803150B2 (en) 2004-04-21 2010-09-28 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US7654997B2 (en) 2004-04-21 2010-02-02 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitus and other disorders of the ears, nose and/or throat
US8702626B1 (en) 2004-04-21 2014-04-22 Acclarent, Inc. Guidewires for performing image guided procedures
US20060004323A1 (en) 2004-04-21 2006-01-05 Exploramed Nc1, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures
US8932276B1 (en) 2004-04-21 2015-01-13 Acclarent, Inc. Shapeable guide catheters and related methods
US9399121B2 (en) 2004-04-21 2016-07-26 Acclarent, Inc. Systems and methods for transnasal dilation of passageways in the ear, nose or throat
US7559925B2 (en) * 2006-09-15 2009-07-14 Acclarent Inc. Methods and devices for facilitating visualization in a surgical environment
US8747389B2 (en) 2004-04-21 2014-06-10 Acclarent, Inc. Systems for treating disorders of the ear, nose and throat
US8764729B2 (en) * 2004-04-21 2014-07-01 Acclarent, Inc. Frontal sinus spacer
US7462175B2 (en) 2004-04-21 2008-12-09 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US7361168B2 (en) 2004-04-21 2008-04-22 Acclarent, Inc. Implantable device and methods for delivering drugs and other substances to treat sinusitis and other disorders
US9101384B2 (en) * 2004-04-21 2015-08-11 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, Nose and/or throat
US10188413B1 (en) 2004-04-21 2019-01-29 Acclarent, Inc. Deflectable guide catheters and related methods
US9089258B2 (en) * 2004-04-21 2015-07-28 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US7419497B2 (en) 2004-04-21 2008-09-02 Acclarent, Inc. Methods for treating ethmoid disease
US9351750B2 (en) 2004-04-21 2016-05-31 Acclarent, Inc. Devices and methods for treating maxillary sinus disease
US7410480B2 (en) * 2004-04-21 2008-08-12 Acclarent, Inc. Devices and methods for delivering therapeutic substances for the treatment of sinusitis and other disorders
US8146400B2 (en) 2004-04-21 2012-04-03 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US20060063973A1 (en) 2004-04-21 2006-03-23 Acclarent, Inc. Methods and apparatus for treating disorders of the ear, nose and throat
US20070167682A1 (en) 2004-04-21 2007-07-19 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
CA2578030A1 (en) * 2004-08-26 2006-03-09 Mallinckrodt Inc. Luminescent metal complexes for monitoring renal function
WO2006037837A1 (en) * 2004-10-01 2006-04-13 Turun Yliopisto Dye particle and its preparation and use
ES2375395T3 (en) 2004-12-23 2012-02-29 Mallinckrodt Llc FLUORESCENT PIRAZINE DERIVATIVES AND METHOD OF USE OF THE SAME IN THE EVALUATION OF RENAL FUNCTION.
US8664392B2 (en) 2004-12-23 2014-03-04 Medibeacon, LLC Pyrazine derivatives for bioconjugation
US8951225B2 (en) 2005-06-10 2015-02-10 Acclarent, Inc. Catheters with non-removable guide members useable for treatment of sinusitis
US8114113B2 (en) 2005-09-23 2012-02-14 Acclarent, Inc. Multi-conduit balloon catheter
US20070179518A1 (en) * 2006-02-02 2007-08-02 Becker Bruce B Balloon Catheters and Methods for Treating Paranasal Sinuses
US8758723B2 (en) * 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
US8190389B2 (en) * 2006-05-17 2012-05-29 Acclarent, Inc. Adapter for attaching electromagnetic image guidance components to a medical device
JP2009534396A (en) 2006-06-22 2009-09-24 マリンクロッド・インコーポレイテッド Pyrazine derivatives and their use in kidney monitoring
CA2655857C (en) 2006-06-22 2014-12-02 Mallinckrodt Inc. Pyrazine derivatives with extended conjugation and uses thereof
US7805183B2 (en) * 2006-06-22 2010-09-28 Wisconsin Alumni Research Foundation Stromal collagen in the diagnosis and characterization of breast cancer
US9820688B2 (en) 2006-09-15 2017-11-21 Acclarent, Inc. Sinus illumination lightwire device
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
US20080085563A1 (en) * 2006-10-10 2008-04-10 Idexx Laboratories, Inc. Detection of Gadolinium Chelates
US20080085562A1 (en) * 2006-10-10 2008-04-10 Idexx Laboratories, Inc. Detection of gadolinium chelates
US8439687B1 (en) 2006-12-29 2013-05-14 Acclarent, Inc. Apparatus and method for simulated insertion and positioning of guidewares and other interventional devices
US8144966B2 (en) * 2007-03-02 2012-03-27 Wisconsin Alumni Research Foundation Use of endogenous fluorescence to identify invading metastatic breast tumor cells
US7996068B2 (en) * 2007-03-14 2011-08-09 The Board Of Trustees Of The Leland Stanford Junior University Surgical method and apparatus for identification of fluorescence
US8118757B2 (en) 2007-04-30 2012-02-21 Acclarent, Inc. Methods and devices for ostium measurement
US8485199B2 (en) 2007-05-08 2013-07-16 Acclarent, Inc. Methods and devices for protecting nasal turbinate during surgery
US20090030409A1 (en) * 2007-07-27 2009-01-29 Eric Goldfarb Methods and devices for facilitating visualization in a surgical environment
US10206821B2 (en) 2007-12-20 2019-02-19 Acclarent, Inc. Eustachian tube dilation balloon with ventilation path
US8182432B2 (en) 2008-03-10 2012-05-22 Acclarent, Inc. Corewire design and construction for medical devices
US8979888B2 (en) 2008-07-30 2015-03-17 Acclarent, Inc. Paranasal ostium finder devices and methods
CN103623498B (en) * 2008-09-18 2015-12-30 阿克拉伦特公司 Be used for the treatment of the method and apparatus of otorhinolaryngology disease
US8697033B2 (en) 2008-12-17 2014-04-15 Medibeacon, LLC Modified pyrazine derivatives and uses thereof
US20100241155A1 (en) 2009-03-20 2010-09-23 Acclarent, Inc. Guide system with suction
US8435290B2 (en) * 2009-03-31 2013-05-07 Acclarent, Inc. System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx
US7978742B1 (en) 2010-03-24 2011-07-12 Corning Incorporated Methods for operating diode lasers
US20110160740A1 (en) * 2009-12-28 2011-06-30 Acclarent, Inc. Tissue Removal in The Paranasal Sinus and Nasal Cavity
US9155492B2 (en) 2010-09-24 2015-10-13 Acclarent, Inc. Sinus illumination lightwire device
JP2015510436A (en) * 2012-02-17 2015-04-09 ファーマコフォトニクス，インコーポレイティド Compositions and methods for monitoring biomarkers
US9433437B2 (en) 2013-03-15 2016-09-06 Acclarent, Inc. Apparatus and method for treatment of ethmoid sinusitis
US9629684B2 (en) 2013-03-15 2017-04-25 Acclarent, Inc. Apparatus and method for treatment of ethmoid sinusitis
JP2014221117A (en) * 2013-05-13 2014-11-27 株式会社アライ・メッドフォトン研究所 Therapy progress degree monitoring device and method for therapy progress degree monitoring
CA2927004C (en) 2013-10-22 2022-10-04 Ralf Heinrich Improved transcutaneous organ function measurement
US11001562B2 (en) * 2013-10-31 2021-05-11 Beth Israel Deaconess Medical Center Near-infrared fluorescent nerve contrast agents and methods of use thereof
SG10201804505VA (en) * 2013-10-31 2018-07-30 Beth Israel Deaconess Medical Ct Inc Near-infrared fluorescent contrast bioimaging agents and methods of use thereof
IL268333B (en) 2017-01-30 2022-07-01 Medibeacon Inc Method for non-invasive monitoring of fluorescent tracer agent with background separation corrections

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000001663A1 (en) * 1998-07-07 2000-01-13 Smithkline Beecham Corporation Novel fluorescent lanthanide chelates
WO2001023005A1 (en) * 1999-09-24 2001-04-05 Schering Aktiengesellschaft Antibody dye conjugates for binding to target structures of angiogenesis in order to intraoperatively depict tumor peripheries

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE402356B (en) 1977-01-19 1978-06-26 Wallac Oy PROCEDURE TO OPTIMIZE THE METHOD TIME IN AN INSTRUMENT FOR RADIOACTIVE SAMPLES RADIATION
SE428332B (en) 1979-03-08 1983-06-20 Wallac Oy PROCEDURE FOR FLUORESCENSE SPECTROSCOPIC DETERMINATION OF BIOLOGICALLY ACTIVE SUBSTANCE, LIKE HAPTEN, ANTIBODY OR ANTIGEN
US4428744A (en) 1979-12-11 1984-01-31 Frederic A. Bourke, Jr. Method and system for externally treating the blood
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
SE454115B (en) 1982-09-13 1988-03-28 Wallac Oy HOMOGENIC PHASE ANALYSIS WITH LANTANIDE KELAT AS BRAND SUBSTANCE
SE8301395L (en) 1983-03-15 1984-09-16 Wallac Oy KELATIZING COMPOUNDS WITH FUNCTIONAL GROUPS WHICH ALLOW COVALENT COUPLING TO BIO-ORGANIC MOLECULES
US5585279A (en) 1986-01-23 1996-12-17 Davidson; Robert S. Time-resolved luminescence binding assays using a fluorescent transition metal label other than ruthenium
GB8602304D0 (en) 1986-01-30 1986-03-05 Dakubu S Dihydropyridine condensation products
US5334371A (en) * 1988-07-20 1994-08-02 Schering Aktiengesellschaft Marcocyclic polyaza bicyclo compounds containing 5 or 6 membered rings, and method for MRI
US4976950A (en) 1988-12-19 1990-12-11 The Dow Chemical Company Bone marrow suppressing agents
US4882142A (en) 1988-12-19 1989-11-21 The Dow Chemical Company Bone marrow suppressing agents
US5627036A (en) * 1989-12-27 1997-05-06 Boehringer Ingelheim International Gmbh Use of an anticoagulant as a diagnostic agent
FI88654C (en) 1991-03-15 1993-06-10 Datacity Center Oy Fluorescenshoejningsmetod
US5301673A (en) 1991-11-18 1994-04-12 Massachusetts General Hospital Ambulatory clearance function monitor
ATE160943T1 (en) 1991-12-10 1997-12-15 Dow Chemical Co BICYCLOAZAMACROCYCLOPHOSPHONE ACID, COMPLEXES, CONJUGATES, CONTRAST AGENTS AND PREPARATION
US5468467A (en) 1993-04-23 1995-11-21 Bracco International B.V. Methods for the in vivo measurement of the concentration of non-imaging nmr-detectable xenobiotic compounds
US5622821A (en) * 1994-06-29 1997-04-22 The Regents Of The University Of California Luminescent lanthanide chelates and methods of use
US5660991A (en) 1994-10-28 1997-08-26 Lakowicz; Joseph R. Long lifetime anisotropy (polarization) probes for clinical chemistry, immunoassays, affinity assays and biomedical research
KR20000010533A (en) * 1996-04-19 2000-02-15 텍사스 테크 유니버시티 Fluorescent chelates as visual tissue specific imaging agents
US5928625A (en) * 1997-03-13 1999-07-27 Mallinckrodt Inc. Method of measuring physiological function

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000001663A1 (en) * 1998-07-07 2000-01-13 Smithkline Beecham Corporation Novel fluorescent lanthanide chelates
WO2001023005A1 (en) * 1999-09-24 2001-04-05 Schering Aktiengesellschaft Antibody dye conjugates for binding to target structures of angiogenesis in order to intraoperatively depict tumor peripheries

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
AIME S ET AL: "High-resolution NMR and relaxometric studies of Ln(III) complexes of relevance to MRI", JOURNAL OF ALLOYS AND COMPOUNDS, ELSEVIER SEQUOIA, LAUSANNE, CH, vol. 225, 15 July 1995 (1995-07-15), pages 274 - 278, XP004072071, ISSN: 0925-8388 *
BOMBIERI G: "Structure and bonding in lanthanide(III) complexes with macrocyclic ligands", JOURNAL OF ALLOYS AND COMPOUNDS, ELSEVIER SEQUOIA, LAUSANNE, CH, vol. 249, no. 1-2, 15 March 1997 (1997-03-15), pages 76 - 82, XP004083540, ISSN: 0925-8388 *
BUNZLI J-C G ET AL: "Trivalent lanthanide ions: versatile coordination centers with unique spectroscopic and magnetic properties", JOURNAL OF ALLOYS AND COMPOUNDS, ELSEVIER SEQUOIA, LAUSANNE, CH, vol. 303-304, May 2000 (2000-05-01), pages 66 - 74, XP004204337, ISSN: 0925-8388 *
ELSTER A D ET AL: "Dyke award. Europium-DTPA: A gadolinium analogue traceable by fluorescence microscopy", AMERICAN JOURNAL OF NEURORADIOLOGY 1989 UNITED STATES, vol. 10, no. 6, 1989, pages 1137 - 1144, XP001088052, ISSN: 0195-6108 *
FRISOLI JOAN K ET AL: "Pharmacokinetics of a fluorescent drug using laser-induced fluorescence.", CANCER RESEARCH, vol. 53, no. 24, 1993, pages 5954 - 5961, XP001109447, ISSN: 0008-5472 *
GERALDES C F G C ET AL: "Relaxometry, animal biodistribution, and magnetic resonance imaging studies of some new gadolinium (III) macrocyclic phosphinate and phosphonate monoester complexes", MAGNETIC RESONANCE IN MEDICINE 1993 UNITED STATES, vol. 30, no. 6, 1993, pages 696 - 703, XP001092808, ISSN: 0740-3194 *
GRONBERG T ET AL: "Non-invasive estimation of kidney function by x-ray fluorescence analysis. Method for in vivo measurements of iodine-containing contrast media in rabbits", PHYSICS IN MEDICINE AND BIOLOGY 1981 UNITED KINGDOM, vol. 26, no. 3, 1981, pages 501 - 506, XP001109191 *
GUDGIN DICKSON E F ET AL: "TIME-RESOLVED DETECTION OF LANTHANIDE LUMINESCENCE FOR ULTRASENSITVE BIOANALYTICAL ASSAYS", JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B: BIOLOGY, ELSEVIER SCIENCE S.A., BASEL, CH, vol. 27, no. 1, 1995, pages 3 - 19, XP001018129, ISSN: 1011-1344 *
KUMAR K: "Macrocyclic polyamino carboxylate complexes of Gd(III) as magnetic resonance imaging contrast agents", JOURNAL OF ALLOYS AND COMPOUNDS, ELSEVIER SEQUOIA, LAUSANNE, CH, vol. 249, no. 1-2, 15 March 1997 (1997-03-15), pages 163 - 172, XP004083559, ISSN: 0925-8388 *
LAUB G: "Principles of contrast-enhanced MR angiography: Basic and clinical applications", MAGNETIC RESONANCE IMAGING CLINICS OF NORTH AMERICA 1999 UNITED STATES, vol. 7, no. 4, 1999, pages 783 - 795, XP008011225, ISSN: 1064-9689 *
MARQUES M P M ET AL: "NMR conformational study of the lanthanide(III) complexes of DOTA in aqueous solution", JOURNAL OF ALLOYS AND COMPOUNDS, ELSEVIER SEQUOIA, LAUSANNE, CH, vol. 225, 15 July 1995 (1995-07-15), pages 303 - 307, XP004072065, ISSN: 0925-8388 *
PETERS A M ET AL: "Measurement of the extravascular concentration of renal agents following intravenous bolus injection.", NUCLEAR MEDICINE COMMUNICATIONS, vol. 15, no. 2, 1994, pages 66 - 72, XP001131924, ISSN: 0143-3636 *
TAKADA K: "Effectiveness of DTPA for the removal of in vivo 144 Ce accompanied with different levels of carrier.", HEALTH PHYSICS. UNITED STATES OCT 1972, vol. 23, no. 4, October 1972 (1972-10-01), pages 481 - 489, XP001109190, ISSN: 0017-9078 *

Also Published As

Publication number Publication date
JP2004517041A (en) 2004-06-10
US20030017111A1 (en) 2003-01-23
WO2002005858A2 (en) 2002-01-24
AU2001280647A1 (en) 2002-01-30
US6440389B1 (en) 2002-08-27
EP1427451A2 (en) 2004-06-16
CA2418206A1 (en) 2002-01-24

Similar Documents

Publication Publication Date Title
WO2002005858A3 (en) Fluorescent agents for real-time measurement of organ function
CA2421007A1 (en) Method for detection of htr and htert telomerase-associated rna in plasma or serum
CA2322858A1 (en) Detection of analytes by fluorescent lanthanide chelates
CA2435550A1 (en) System for monitoring the concentration of analytes in body fluids
WO1997022878A3 (en) Reagent and method for differential determination of leukocytes in blood
SI0670310T1 (en) Bisulfite adducts of arginine aldehydes useful as thrombin inhibitors and as anticoagulants
AU2001242309A1 (en) A disposable lancet combined with a reagent carrying strip and a system for extracting and analysing blood in the body utilizing such a disposable lancet
WO2002062397A3 (en) Chelates of metals which can be activated by neutrons and their use for the measurement of labeled specimens
WO2002038204A3 (en) Occlusion detection method and system for ambulatory drug infusion pump
EP1281960A3 (en) Methods and devices for use in analyte concentration determination assays
WO1996042015A3 (en) Reagent and method for differential determination of leukocytes in blood
BR9912339A (en) Fluid collection and sensor device for placing over at least one artificial opening made in a biological membrane to measure a characteristic of a biological fluid and processes for monitoring a characteristic of a biological fluid collected from at least one artificial opening in a tissue and for maintaining a flow of a biological fluid through a device that continuously collects and measures a characteristic of a biological fluid.
Olson et al. Hydroxamate-based histone deacetylase inhibitors can protect neurons from oxidative stress via a histone deacetylase-independent catalase-like mechanism
EP0924520A3 (en) A sensor and a set of sensors
WO2001044819A3 (en) Hematological assay and reagent
EP1226829A3 (en) Stabilised liquid preparations of the protease or its proenzyme which activitate the blood coagulation factor VII
WO2002095358A3 (en) System and method for monitoring or treating a health condition
EP1211512A3 (en) Test strip for determining dialysate composition
EP1445329A3 (en) Method and test strip for determining glucose in blood
AU2001259476A1 (en) Assay for detecting, measuring and monitoring the activities and concentrations of proteins and methods of use thereof
EP1451342A4 (en) Low molecular weight heparin assay, system and reagent therefor
WO1993017332A1 (en) Gas chromatography/mass spectrometry determination of ascorbate and oxidation products thereof
Galvin et al. Urinary excretion of beta‐hydroxybutyrate and acetoacetate during experimental ketosis
WO2004092728A3 (en) Methods of measuring the ability of a test compound to inactivate a biological target in cells of a subject
BR0111726A (en) Biotin Derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2418206

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001959055

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10204511

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001959055

Country of ref document: EP